Thursday, January 12, 2017 5:03:18 PM
My take is they could parcel out the Melanoma combo program for non-responders. But whether the IND is picked up as well will probably be negotiable in the deal. Punit has always tried to position the company to go it alone so they always can move forward with their science. They have Australia set up as a go-it-alone option, but also expressed the desire for a "global" registration trial and the wish to partner with one of only two PD-1 drug companies that meet those requirments--Merck's Ketruda and BMS's Yervoy. Of coarse Merck would be preferred but obviously no deal yet.
I'm also curious as to how they farm out the IL-12 melanoma platform for just Melanoma, when the IL-12 + Combo platform, has potential across all indications, with even greater accuracy with TRACE. I think the Monetizing of TRACE will help calculations of ImmunnoPulse treatment cost per patient and over-all valuation of company in estimating platform/company exit opportunity valuation.
Recent ONCSQ News
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/13/2024 07:30:19 PM
Avant Technologies Engages Wired4Tech to Evaluate the Performance of Next Generation AI Server Technology • AVAI • May 23, 2024 8:00 AM
Branded Legacy, Inc. Unveils Collaboration with Celebrity Tattoo Artist Kat Tat for New Tattoo Aftercare Product • BLEG • May 22, 2024 8:30 AM
"Defo's Morning Briefing" Set to Debut for "GreenliteTV" • GRNL • May 21, 2024 2:28 PM
North Bay Resources Announces 50/50 JV at Fran Gold Project, British Columbia; Initiates NI 43-101 Resources Estimate and Bulk Sample • NBRI • May 21, 2024 9:07 AM
Greenlite Ventures Inks Deal to Acquire No Limit Technology • GRNL • May 17, 2024 3:00 PM
Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • SONGD • May 17, 2024 11:00 AM